Skip to main content
Premium Trial:

Request an Annual Quote

Genomics Inks Drug Screening Deal With Biogen

NEW YORK (GenomeWeb) – Genomics plc, an Oxford, UK-based bioinformatics company, announced today that it has inked a deal with Biogen to screen drug targets for the firm.

Genomics will use its genomic data analysis and interpretation capabilities to refine Biogen’s drug target selection. The firm's platform combines proprietary algorithms and software with its integrated genome-phenome database and analytical expertise to uncover relationships between genetic variation and human health outcomes, it said.

"This agreement highlights the growing commitment within the pharmaceutical and biotech industries to systematically use human genetic data in research to increase the chance of success in drug development," Genomics CEO John Colenutt said in a statement.

Terms of the agreement were not disclosed.

Earlier this year, the firm inked a collaboration with Eisai's Integrated Human Genomics research unit, which focuses on developing therapies primarily for neurodegeneration, autoimmune diseases, and oncology.

The Scan

International Team Proposes Checklist for Returning Genomic Research Results

Researchers in the European Journal of Human Genetics present a checklist to guide the return of genomic research results to study participants.

Study Presents New Insights Into How Cancer Cells Overcome Telomere Shortening

Researchers report in Nucleic Acids Research that ATRX-deficient cancer cells have increased activity of the alternative lengthening of telomeres pathway.

Researchers Link Telomere Length With Alzheimer's Disease

Within UK Biobank participants, longer leukocyte telomere length is associated with a reduced risk of dementia, according to a new study in PLOS One.

Nucleotide Base Detected on Near-Earth Asteroid

Among other intriguing compounds, researchers find the nucleotide uracil, a component of RNA sequences, in samples collected from the near-Earth asteroid Ryugu, as they report in Nature Communications.